120 related articles for article (PubMed ID: 6776543)
41. [Use of teronak for the treatment of obesity with and without diabetes mellitus].
Egart FM; Korotkova VD
Probl Endokrinol (Mosk); 1980; 26(2):16-20. PubMed ID: 7375451
[TBL] [Abstract][Full Text] [Related]
42. Changes of blood levels of several hormones, catecholamines, prostaglandins, electrolytes and cAMP in man during emotional stress.
Tigranian RA; Orloff LL; Kalita NF; Davydova NA; Pavlova EA
Endocrinol Exp; 1980; 14(2):101-12. PubMed ID: 6248318
[TBL] [Abstract][Full Text] [Related]
43. Double-blind evaluation of the effects of mazindol on pain, depression, anxiety, appetite, and activity in terminal cancer patients.
Bruera E; Carraro S; Roca E; Barugel M; Chacon R
Cancer Treat Rep; 1986 Feb; 70(2):295-8. PubMed ID: 3512080
[TBL] [Abstract][Full Text] [Related]
44. [Mazindol (AN-448): a new non-amphetamine anorectic in the treatment of exogenous obesity].
Delitala G; Alagna S; Masala A
Clin Ter; 1977 Jun; 81(6):547-54. PubMed ID: 884939
[No Abstract] [Full Text] [Related]
45. Growth and luteinizing hormone decreases during nafenoic acid therapy.
Danowski TS; Fisher ER; Gonzalez AR; Khurana RC; Jung Y; Hancock RA; Vester JW
Pol Med Sci Hist Bull; 1971 Oct; 14(4):148-53. PubMed ID: 5131072
[No Abstract] [Full Text] [Related]
46. [Activity-mobilizing lipids and blood lipids in patients treated with Mazindol].
Hasik J; Gryczka AZ; Paluszak J; Tycowa M
Pol Arch Med Wewn; 1978 Nov; 60(5):401-4. PubMed ID: 724542
[No Abstract] [Full Text] [Related]
47. [Clinical use of mazindol in the treatment of essential obesity].
Guazzelli R; Piazzini M; Conti C; Papi L; Strazzulla G; Matassi L
Clin Ter; 1987 Mar; 120(5):385-91. PubMed ID: 2953538
[No Abstract] [Full Text] [Related]
48. Effect of anorexiant drugs on growth hormone secretion in obese children.
Baritussio A; Enzi G; Rigon G; Molinari M; Inelmen EM; Crepaldi G
Pharmacol Res Commun; 1978 Jun; 10(6):529-40. PubMed ID: 693565
[No Abstract] [Full Text] [Related]
49. [Mazindol in the treatment of obese diabetic patients].
Dolecek R; Reil P; Skarpová O; Závada M
Vnitr Lek; 1976 Aug; 22(8):798-804. PubMed ID: 788327
[No Abstract] [Full Text] [Related]
50. A multi-centre general practice trial of mazindol in the treatment of obesity.
Maclay WP; Wallace MG
Practitioner; 1977 Mar; 218(1305):431-4. PubMed ID: 322112
[No Abstract] [Full Text] [Related]
51. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan.
Inoue S; Egawa M; Satoh S; Saito M; Suzuki H; Kumahara Y; Abe M; Kumagai A; Goto Y; Shizume K
Am J Clin Nutr; 1992 Jan; 55(1 Suppl):199S-202S. PubMed ID: 1728834
[TBL] [Abstract][Full Text] [Related]
52. [Treatment of obesity with mazindol (author's transl)].
Escher M
Schweiz Rundsch Med Prax; 1976 Jun; 65(24):751-4. PubMed ID: 981189
[No Abstract] [Full Text] [Related]
53. Clinical studies with mazindol.
Inoue S
Obes Res; 1995 Nov; 3 Suppl 4():549S-552S. PubMed ID: 8697057
[TBL] [Abstract][Full Text] [Related]
54. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity.
Enzi G; Baritussio A; Marchiori E; Crepaldi G
J Int Med Res; 1976; 4(5):305-18. PubMed ID: 1028632
[TBL] [Abstract][Full Text] [Related]
55. Ciclazindol and mazindol on glucose uptake into human isolated skeletal muscle: no interaction of mazindol with methysergide.
Kirby MJ; Turner P
Br J Clin Pharmacol; 1977 Aug; 4(4):459-61. PubMed ID: 901738
[TBL] [Abstract][Full Text] [Related]
56. A multicentre study comparing mazindol and placebo in obese patients.
Walker BR; Ballard IM; Gold JA
J Int Med Res; 1977; 5(2):85-90. PubMed ID: 326596
[TBL] [Abstract][Full Text] [Related]
57. [Mazindol (AN 448 Sandoz) in ambulatory treatment of obesity; its effect on body composition and adipose tissue].
Rath R; Vondra K; Wenkeová J
Cesk Gastroenterol Vyz; 1977 Sep; 31(6):389-94. PubMed ID: 589677
[No Abstract] [Full Text] [Related]
58. Double blind cross-over study of a new appetite suppressant AN 448.
Haugen HN
Eur J Clin Pharmacol; 1975; 8(1):71-4. PubMed ID: 786676
[TBL] [Abstract][Full Text] [Related]
59. [Modification of serum lipid values and of the neurovegetative equilibrium in subjects under mazindol therapy].
Zdichynec B; Rechmani BA
Cesk Gastroenterol Vyz; 1979 Jan; 33(1):51-7. PubMed ID: 369713
[No Abstract] [Full Text] [Related]
60. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy.
Coakley JH; Moorcraft J; Hipkin LJ; Smith CS; Griffiths RD; Edwards RH
J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1551-7. PubMed ID: 3221222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
